Navigation Links
Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment
Date:11/24/2008

NEW BRUNSWICK, N.J., Nov. 24 /PRNewswire-USNewswire/ -- James M. Golubieski, president of Foundation Venture Capital Group, LLC, a New Jersey Health Foundation affiliate, announced today that the company has made a $500,000 commitment to Longevica Pharmaceuticals, Inc., a company involved in developing kinase inhibitors that may keep normal cells healthy during chemotherapy or radiation treatments.

The company is a start-up at the University of Medicine and Dentistry of New Jersey.

"Despite the tremendous progress in chemotherapy and radiation use to treat cancer patients, most of the drugs available today are extremely toxic, not only killing cancer cells but also killing normal cells," explained Alexey Ryazanov, PhD, founder and president of Longevica. "Our company is working to develop approaches to help protect normal tissue during chemotherapy and radiation treatment."

Longevica scientists discovered that if the EF2 kinase (a protein involved in the regulation of protein synthesis in human cells) can be rendered inactive, normal cells could be protected from dying during chemotherapy and radiation treatment. Not only does this process protect normal tissues from dying, says Dr. Ryazanov, but it also renders the cancer-killing treatment more effective.

"The work of Dr. Ryazanov and the scientists at Longevica is so exciting because currently, there is no such therapy available," explained George F. Heinrich, MD, vice chair and CEO of Foundation Venture Capital Group. "A breakthrough in the use of this kinase could positively affect millions of people undergoing cancer treatments. We are proud that Foundation Venture Capital Group is able to help move Longevica's research to the next level of study."

In addition to helping cancer patients undergoing treatment, preliminary studies also indicate the same drug can be used to help patients who have had strokes by protecting cells and tissues from cell death in the heart and brain. It may also prevent the progressive loss of neurons in patients with Alzheimer's or Parkinson's disease

Foundation Venture Capital Group was founded in 2006 to invest in commercially viable new start-up companies developing technology at the University of Medicine & Dentistry of New Jersey. Longevica Pharmaceuticals, Inc., is its third investment.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
3. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
4. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
7. The Tug McGraw Foundation Announces 2007 Fundraising Gala
8. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
9. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
10. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
11. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Physician Partners ... Fla. location at 5304 Main Street as an interventional pain management specialist. , ... and extremities. He joins PPOA from private practice In Brooksville, Fla. His orthopedic background ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often happens ... Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s Director ... us to come over before the baby had to go back to her grandparents. ...
(Date:9/25/2017)... ... September 25, 2017 , ... The trend-spotters, tastemakers, and healthy lifestyle product experts ... based super herb drinks, with the new NEXTY Gold Award at the Natural Products ... the NEXTY Gold, which is reserved for just those companies that hit high marks ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our ... questions of life and seeks answers in both Eastern and Western religious traditions and ... God is in the mind of humankind for the past thousands of years and ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
Breaking Medicine Technology: